troglitazone has been researched along with Cytokine Release Syndrome in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fatal influenza (flu) virus infection often activates excessive inflammatory signals, leading to multi-organ failure and death, also referred to as cytokine storm." | 1.72 | Influenza virus causes lung immunopathology through down-regulating PPARĪ³ activity in macrophages. ( Alford, T; Liu, S; Wang, J; Zhang, H; Zhou, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Alford, T | 1 |
| Liu, S | 1 |
| Zhou, D | 1 |
| Wang, J | 1 |
1 other study available for troglitazone and Cytokine Release Syndrome
| Article | Year |
|---|---|
Influenza virus causes lung immunopathology through down-regulating PPARĪ³ activity in macrophages.
Topics: Acute Lung Injury; Animals; Antiviral Agents; Cytokine Release Syndrome; Humans; Influenza, Human; L | 2022 |